King International Investment Limited (928) announced its unaudited interim results for the six months ended 30 September 2025, reporting a notable turnaround with a profit of approximately HK$7.42 million, compared to a loss of about HK$1.59 million for the same period in 2024. Revenue rose by about 98.8% to HK$73.92 million, up from HK$37.19 million in the previous year’s interim period.

The higher revenue was largely driven by two core segments: healthcare products and services and sales of liquor. The healthcare segment contributed around HK$15.18 million in sales, whereas there was no revenue from this segment in the prior year’s interim period. The sales of liquor business recorded HK$58.74 million during the current period, compared to HK$37.19 million in the first half of 2024. Overall gross profit margin improved to 10.55%, compared to 2.71% in the corresponding period last year.

In the healthcare segment, contributions derived from the trading of disinfectant water played a part in increased turnover. The announcement also highlights continued development in special enzyme technology, with this area expected to further enrich the healthcare product offerings. The liquor segment, which markets Maotai-flavor liquor under the “Diwangchi” brand, registered a profit of HK$2.92 million and is anticipated to remain a key revenue contributor.

As at 30 September 2025, the Group held cash and cash equivalents of HK$0.6 million and recorded total net assets of approximately HK$234.80 million. The company reported having 13 employees (excluding directors). No interim dividend was declared.

Looking ahead, management intends to focus on improving efficiency, expanding brand visibility in the growing liquor market, and cultivating new opportunities within the healthcare businesses. The Group aims to leverage these initiatives to support higher profitability and enhance overall performance in the future.